Loading...

News List

Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib

2022-06-13


Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03252587) of the novel oral TYK2 inhibitor deucravicitinib in moderate-to-severe systemic lupus erythematosus (SLE) at the European Union of Rheumatology Association (EULAR) 2022 Congress. result. The data showed that the study met its primary endpoint of SRI-4 (SLE Responder Index 4) response at week 32 of treatment. SRI-4 is a composite endpoint used in SLE clinical trials to assess disease activity.

Pre: Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)

Next: Vijoice is the first FDA-approved PRS treatment

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.